SK Bioscience submits its COVID vaccine for phase 3 clinical trial as South Korea grapples with surging delta variant

SOUTH KOREA – SK Bioscience has submitted its application for the phase 3 clinical trials of its COVID vaccine, GBP510, to the to the Ministry of Food and Drug Safety (MFDS). GBP510, a COVID-19 vaccine candidate supported by Bill & Melinda Gates Foundation (BMGF) and Coalition for Epidemic Preparedness Innovations (CEPI) and co-developed with the Institute for Protein Design (IPD) at the University of Washington will become the first COVID vaccine developed in Korea to be submitted to MFDS. The company also plans to apply for phase 3 clinical trial…

Read More